The United States of America as Represented by the Department of Health

Opiant Pharmaceuticals, Inc.

Otsuka America Pharmaceutical, Inc.

Phil Skolnick

Kenneth Alan Jacobson

Kenner C Rice

Zhengming Chen

Ramon Trullas

Anita H Lewin

R Tyler McCabe

James A Monn

Juan-Carlos Marvizon

Claudia P Faiman

Eugenia Viu

Disclosed herein are formulations and methods for reversing one or more symptoms of cannabinoid hyperemesis syndrome (CHS) or one or more symptoms thereof, comprising parenterally administering a CB1 antagonist in an amount sufficient to reverse the CHS or symptom(s).

Compositions and methods for treating cannabinoid hyperemesis syndrome with a cannabinoid receptor antagonist

A method is disclosed for the treatment of neuropsychopharmacological disorders which are associated with or result from excessive activation of the N-methyl-D-aspartate receptor complex, which method comprises administering an effective neuropsychopharmacological disorder-treating amount of a compound possessing partial agonist properties for the strychnine insensitive glycine modulatory sites of N-methyl-D-aspartate receptors. Exemplary of partial agonists which are useful in the method of the invention are 1-aminocyclopropanecarboxylic acid, and associated derivates thereof. Novel injectable pharmaceutical compositions are also disclosed.

Partial agonists of the strychnine insensitive glycine modulatory site

The use of a compound possessing functional antagonist properties at the NMDA receptor complex through a specific action at the associated strychnine-insensitive glycine site to improve cognition in normal humans and to treat cognitive deficits resulting from chronic neuronal degeneration, acute brain injury, hypoxia, or other neurological disorders is provided. The compounds possessing functional antagonist properties comprise 1-aminocyclopropanecarboxylic acid, and its pharmaceutically acceptable esters, salts, and acid addition salts or 7-chlorokynurenic acid, and its pharmaceutically acceptable esters, amides, salts, ethers, and acid addition salts.

Treating cognition with, aminocyclopropanecarboxylic derivatives

The present invention is directed to compounds useful as probes for characterizing and studying the adenosine A.sub.2 receptor. The present invention is also directed to methods of treating central nervous system disorders and cardiovascular disorders which include treating hypertension and thrombosis by administering said compounds.

2-substituted adenosines and 2-substituted adenosine 5'-carboxamides

A method is disclosed for the treatment of mood disorders, including major depression, by administering an effective mood disorder treating amount of a compound possessing functional antagonist properties for the N-methyl-D-aspartate receptor complex.

Growing community of inventors

Potomac, MD, United States of America

Phil Skolnick